Close Menu

Lung Cancer

News and reporting on lung cancer.

Using mass spec and small hairpin RNA, they built a map of ALK signaling and identified proteins that could sensitize tumor cells to inhibitor treatment.

Repeat molecular analysis of a patient's cancer helped clinicians guide targeted therapies as drug resistance emerged and ebbed.

Pfizer's Xalkori yielded significantly longer progression-free survival than standard chemotherapy in the Phase III trial of first-line treatment of ALK-positive NSCLC.

Pages